BSE Live
Mar 20, 16:01Prev. Close
207.30
Open Price
208.65
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 20, 15:59Prev. Close
207.19
Open Price
210.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Bliss GVS Pharma (in Rs. Cr.) | Mar 05 | Mar 04 | |
| Per Share Ratios | |||
| Basic EPS (Rs.) | 1.63 | 1.14 | |
| Diluted EPS (Rs.) | 1.63 | 1.14 | |
| Cash EPS (Rs.) | 1.92 | 1.37 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 14.10 | 12.47 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 14.10 | 12.47 | |
| Dividend / Share(Rs.) | 0.00 | 1.00 | |
| Revenue from Operations/Share (Rs.) | 16.46 | 12.72 | |
| PBDIT/Share (Rs.) | 2.84 | 1.86 | |
| PBIT/Share (Rs.) | 2.55 | 1.62 | |
| PBT/Share (Rs.) | 2.49 | 1.57 | |
| Net Profit/Share (Rs.) | 1.63 | 1.14 | |
| Profitability Ratios | |||
| PBDIT Margin (%) | 17.26 | 14.58 | |
| PBIT Margin (%) | 15.50 | 12.74 | |
| PBT Margin (%) | 15.11 | 12.35 | |
| Net Profit Margin (%) | 9.93 | 8.92 | |
| Return on Networth / Equity (%) | 11.59 | 9.10 | |
| Return on Capital Employed (%) | 10.95 | 8.54 | |
| Return on Assets (%) | 7.08 | 5.35 | |
| Total Debt/Equity (X) | 0.03 | 0.04 | |
| Asset Turnover Ratio (%) | 71.26 | 59.98 | |
| Liquidity Ratios | |||
| Current Ratio (X) | 2.12 | 2.29 | |
| Quick Ratio (X) | 1.79 | 1.96 | |
| Inventory Turnover Ratio (X) | 6.09 | 4.97 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 88.48 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 73.35 | |
| Earnings Retention Ratio (%) | 100.00 | 11.52 | |
| Cash Earnings Retention Ratio (%) | 100.00 | 26.65 | |
| Valuation Ratios | |||
| Enterprise Value (Cr.) | 5.10 | 1.16 | |
| EV/Net Operating Revenue (X) | 1.20 | 0.35 | |
| EV/EBITDA (X) | 6.93 | 2.42 | |
| MarketCap/Net Operating Revenue (X) | 1.40 | 0.71 | |
| Retention Ratios (%) | 100.00 | 11.51 | |
| Price/BV (X) | 1.63 | 0.73 | |
| Price/Net Operating Revenue | 1.40 | 0.71 | |
| Earnings Yield | 0.07 | 0.13 |
20.02.2026
Bliss GVS Consolidated December 2025 Net Sales at Rs 218.25 crore, up 3.72% Y-o-Y
19.02.2026
Bliss GVS Standalone December 2025 Net Sales at Rs 164.68 crore, down 8.3% Y-o-Y
07.11.2025
Bliss GVS Consolidated September 2025 Net Sales at Rs 244.40 crore, up 12.27% Y-o-Y
30.07.2025
Bliss GVS Consolidated June 2025 Net Sales at Rs 207.47 crore, up 12.97% Y-o-Y
20.03.2026
Eris Lifesciences, Natco Pharma to launch generic Ozempic at 90% cheaper price
20.03.2026
Semaglutide’s patent expires today. What does it mean for patients, pharma players and Novo Nordisk?
20.03.2026
20.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth